tradingkey.logo

AtriCure Inc

ATRC
查看详细走势图
40.330USD
-0.220-0.54%
收盘 12/26, 16:00美东报价延迟15分钟
2.00B总市值
亏损市盈率 TTM

AtriCure Inc

40.330
-0.220-0.54%
盘中分时
1分
30分
1小时
日k
周k
月k
日k

今天

-0.54%

5天

-1.51%

1月

+11.93%

6月

+22.66%

今年开始到现在

+31.97%

1年

+31.15%

查看详细走势图

TradingKey AtriCure Inc股票评分

单位: USD 更新时间: 2025-12-26

操作建议

AtriCure Inc当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名12/207位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价51.67。中期看,股价处于上升通道。近一个月,市场表现较强,技术面和基本面综合得分较高,较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间,可以做区间波段操作。

AtriCure Inc评分

相关信息

行业排名
12 / 207
全市场排名
74 / 4563
所属行业
医疗设备与耗材

压力支撑

由于公司未披露,未能获取相关数据

多维评测

本期评分
上期评分

分析师目标

根据 9 位分析师
买入
评级
51.667
目标均价
+32.68%
涨幅空间
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议

AtriCure Inc亮点

亮点风险
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
业绩高增长
公司营业收入稳步增长,连续3年增长40.84%
估值低估
公司最新PE估值-66.36,处于3年历史低位
机构减仓
最新机构持股49.59M股,环比减少0.21%
HACAX持仓
明星投资者HACAX持仓,最新持仓市值28.64K

AtriCure Inc新闻

即将为您带来更多新闻,敬请期待。。。

财务指标

每股收益

由于公司未披露,未能获取相关数据

营业总收入

由于公司未披露,未能获取相关数据

AtriCure Inc简介

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
公司代码ATRC
公司AtriCure Inc
CEOCarrel (Michael H)
网址https://www.atricure.com

常见问题

AtriCure Inc(ATRC)的当前股价是多少?

AtriCure Inc(ATRC)的当前股价是 40.330。

AtriCure Inc的股票代码是什么?

AtriCure Inc的股票代码是ATRC。

AtriCure Inc股票的52周最高点是多少?

AtriCure Inc股票的52周最高点是43.110。

AtriCure Inc股票的52周最低点是多少?

AtriCure Inc股票的52周最低点是28.290。

AtriCure Inc的市值是多少?

AtriCure Inc的市值是2.00B。

AtriCure Inc的净利润是多少?

AtriCure Inc的净利润为-44.70M。

现在AtriCure Inc(ATRC)的股票是买入、持有还是卖出?

根据分析师评级,AtriCure Inc(ATRC)的总体评级为买入,目标价格为51.667。

AtriCure Inc(ATRC)股票的每股收益(EPS TTM)是多少

AtriCure Inc(ATRC)股票的每股收益(EPS TTM)是-0.608。
KeyAI